Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics, Inc.

Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts. 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-19.30M -	-45.70M 136.85%	-120.31M 163.25%	-157.39M 30.81%	-200.07M 27.12%
depreciation and amortization	106K -	1.33M 1,152.83%	1.53M 15.59%	2.80M 82.67%	5.46M 94.54%
deferred income tax	-72K -	380K 627.78%	1.51M 296.84%		-48.01M -
stock based compensation	446K -	850K 90.58%	7.07M 732%	22.48M 217.83%	35.12M 56.23%
change in working capital	2.66M -	2.64M 0.71%	-2.91M 210.22%	8.38M 387.77%	17.70M 111.25%
accounts receivables				-1.01M -	-5.89M 482.21%
inventory				1.01M -
accounts payables	1.74M -	-1.90M 209.39%	6.83M 459.80%	-5.22M 176.38%	3.91M 174.96%
other working capital	926K -	4.54M 390.28%	-9.74M 314.56%	13.60M 239.57%	19.68M 44.79%
other non cash items	8.71M -	5.24M 39.88%	35.23M 572.48%	1.39M 96.04%	40.25M 2,787.59%
net cash provided by operating activities	-7.44M -	-35.27M 373.86%	-77.88M 120.84%	-122.33M 57.08%	-149.55M 22.25%
investments in property plant and equipment	-1.86M -	-3.42M 84.38%	-4.36M 27.31%	-13.23M 203.56%	-9.28M 29.84%
acquisitions net	10.90M -	47.70M 337.60%	234.74M 392.08%	142.72M 39.20%
purchases of investments	-22.00M -	-98.48M 347.63%	-371.49M 277.21%	-479.40M 29.05%	-517.14M 7.87%
sales maturities of investments	11.10M -	50.78M 357.49%	136.75M 169.30%	336.68M 146.19%	554.11M 64.58%
other investing activites	-10.90M -	-47.70M 337.60%	-234.74M 392.08%	-142.72M 39.20%
net cash used for investing activites	-12.76M -	-51.13M 300.74%	-239.10M 367.66%	-155.96M 34.77%	27.69M 117.76%
debt repayment	-110K -
common stock issued	18.04M -	92.63M 413.45%	285.21M 207.92%	326.50M 14.47%	212.58M 34.89%
common stock repurchased
dividends paid
other financing activites	24K -	92.63M 385,845.83%	91.88M 0.81%	2.46M 97.32%
net cash used provided by financing activities	17.95M -	92.63M 415.91%	377.09M 307.10%	328.96M 12.76%	212.58M 35.38%
effect of forex changes on cash					50K -
net change in cash	-2.25M -	6.24M 377.60%	60.11M 864.09%	50.67M 15.71%	90.77M 79.14%
cash at beginning of period	5.47M -	3.22M 41.08%	9.46M 193.57%	69.57M 635.69%	115.41M 65.90%
cash at end of period	3.22M -	9.46M 193.57%	69.57M 635.69%	120.24M 72.83%	206.18M 71.48%
operating cash flow	-7.44M -	-35.27M 373.86%	-77.88M 120.84%	-122.33M 57.08%	-149.55M 22.25%
capital expenditure	-1.86M -	-3.42M 84.38%	-4.36M 27.31%	-13.23M 203.56%	-9.28M 29.84%
free cash flow	-9.30M -	-38.69M 316.06%	-82.24M 112.56%	-135.56M 64.84%	-158.83M 17.16%

COM:VERVETX

Vervet Logic, Inc.

Last Close

4.60

22/11 21:00

Market Cap

507.99M

Beta: -

Volume Today

1.12M

Avg: -

Preview